In the past few months, as the new coronavirus spread to all corners of the world, bringing a lot of grief to people,media BGR reported. The number of new confirmed cases is increasing at an alarming rate, and the number of victims of COVID-19 is increasing. But we have also seen an amazing response in the medical community. Companies are experimenting with new treatments and testing to determine whether existing drugs can be reused to reduce the risk of complications and death from COVID-19. On that basis, other researchers are also working on vaccines, and if all goes well, the first drugs could be deployed on a large scale in some areas as early as 2021.
However, a growing number of teams are working on a new drug that could be used to cure COVID-19 patients and even provide some limited immunity to prevent infection.
These are COVID-19 antibody drugs, a plasma treatment similar to the recovery period. But unlike recovery plasma therapy, these drugs are synthesized in the lab and do not require a donor. Five teams are currently working on antibody therapy in the United States, and promising studies have emerged in Israel, Japan and the Netherlands. These companies use a variety of antibody development techniques, including the reuse of antibodies from other animals, such as camels, to humans.
Efforts to make drugs based on antibodies are larger than expected, according to new reports. South Korea may be the first country to develop the drug, with local company Celltrion planning to begin clinical trials in July. The company could become the first drug developer in the world to propose antibody-based COVID-19 drugs, Business Korea reported.
In addition, Fast Company has detailed similar projects from other pharmaceutical companies that are developing antibody drugs. Regeneron, for example, has two antibody combinations under development and will begin trials in June, even earlier than Celltrion. The latter is being studied with no less than 14 different antibodies. Regeneron said it may have hundreds of thousands of doses of the drug ready by August. The company’s strategy is to target the virus’s protoprotein, which is why it binds to receptors and invades human cells for replication.
GlaxoSmithKline and Vir Biotechnology are working on two drug candidates, and Eli Lilly is working with AbCellera and Junshi Biosciences to develop antibodies. AstraZeneca is also working with Oxford University to develop a promising vaccine and is working on antibodies. In addition, Vanderbilt University is also studying antibody drugs.
Sorrento has partnered with Mount Sinai Medical Center to develop a “COVI-SHIELD” antibody drug that uses mutations to increase the life span of three different antibodies. If the virus mutates, this combination of antibodies should provide better protection. The drugs not only improve the immune response of patients who have been infected with the new coronavirus, but also have the potential to speed recovery — they can also give healthy people temporary immunity with limited use, the report said.
If treatment is successful, they may be able to provide protection for up to two months. Some people who have been working remotely may get an antibody protection when they return to the office and then have another treatment two months later.
For now, this is only theoretical, because research needs to prove the effectiveness of antibody therapy and plasma therapy. But all the anecdotal evidence we’ve seen so far suggests that plasma is effective in PATIENTs with COVID-19, and that artificial antibodies should have the same effect. Fast Company does point out that in some cases, antibody therapy can worsen the infection, which is also a risk that scientists must be prepared.